Create
Log in
Enquire now
Excision BioTherapeutics
Excision BioTherapeutics is a company founded in 2015 and headquartered in Philadelphia.
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Organization
Company
B2X
B2B
CEO
Daniel Dornbusch
CIK Number
1,847,173
Legal Name
Excision BioTherapeutics Inc.
Company Operating Status
Active
Country
United States
Crunchbase URL
crunchbase.com/organiz...apeutics
DUNS Number
080367587
Email Address
info@mysite.com
inquiries@excisionbio.com
Facebook URL
@excisionbio
Founded Date
January 1, 2015
Founder
Thomas Malcolm
Rob Simmons
Full Address
988 Market Street San Francisco, CA 94102 United States
Industry
Healthcare
Consumer biotechnology
Engineering
Tissue engineering
Therapeutics
Biomedical engineering
Biopharmaceutical
Technology
Biology
Biotechnology
•••
Instagram URL
instagram.com/excisionbio/
Investors
ARTIS Ventures
Gaingels
Cota Capital
Norwest Venture Partners
Alumni Ventures Group
Olive Tree Capital
0
Loreda Holdings
Ben Franklin Technology Partners of Southeastern Pennsylvania
Bioverge
Civilization Ventures
0
•••
Latest Funding Round Date
February 17, 2021
Latest Funding Round Amount (USD)
60,000,000
Latest Funding Type
Venture round
LinkedIn URL
@company/excisionbiotherapeutics
Location
United States
Philadelphia
San Francisco
Philadelphia County, Pennsylvania
Number of Employees (Ranges)
11 – 50
Place of Incorporation
Delaware
Technologies Used
CRISPR
Total Funding Amount (USD)
70,750,000
Twitter URL
@excisionbiotx
Official Website
excision.bio
excisionbio.com
Find more companies like Excision BioTherapeutics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE